Documentation Centre

 

 

  of 187 Next page

Go to page: of

Screenshot Date Categories Title Author Format
Effects of lifestyle modification on patients with resistant hypertension: results of the TRIUMPH randomized clinical trial. Circulation. 2021;144:1212-1226 June 06, 2022 Effects of lifestyle modification on patients with resistant hypertension: results of the TRIUMPH randomized clinical trial. Circulation. 2021;144:1212-1226 Blumenthal JA, Hinderliter AL, Smith PJ, Mabe S, Watkins LL, Craighead L, Ingle K, Tyson C, Lin PH, Kraus WE, Liao L, Sherwood A Key Publications
Effect of 2-year caloric restriction on organ and tissue size in nonobese 21- to 50-year-old adults in a randomized clinical trial: the CALERIE study. Am J Clin Nutr. 2021;114:1295-1303 May 24, 2022 Effect of 2-year caloric restriction on organ and tissue size in nonobese 21- to 50-year-old adults in a randomized clinical trial: the CALERIE study. Am J Clin Nutr. 2021;114:1295-1303 Shen W, Chen J, Zhou J, Martin CK, Ravussin E, Redman LM Key Publications
An exploratory analysis of comparative plasma metabolomic and lipidomic profiling in salt-sensitive and salt-resistant individuals from The Dietary Approaches to Stop Hypertension Sodium Trial. J Hypertens. 2021;39:1972-1981 May 12, 2022 An exploratory analysis of comparative plasma metabolomic and lipidomic profiling in salt-sensitive and salt-resistant individuals from The Dietary Approaches to Stop Hypertension Sodium Trial. J Hypertens. 2021;39:1972-1981 Chaudhary P, Velkoska E, Wainford RD Key Publications
Dose-dependent associations of dietary glycemic index, glycemic load, and fiber with 3-year weight loss maintenance and glycemic status in a high-risk population: A secondary analysis of the diabetes prevention study PREVIEW. Diabetes Care. 2021;44:1672-1681 April 08, 2022 Dose-dependent associations of dietary glycemic index, glycemic load, and fiber with 3-year weight loss maintenance and glycemic status in a high-risk population: A secondary analysis of the diabetes prevention study PREVIEW. Diabetes Care. 2021;44:1672-1681 Zhu R, Larsen TM, Fogelholm M, Poppitt SD, Vestentoft PS, Silvestre MP, Jalo E, Navas-Carretero S, Huttunen-Lenz M et al. Key Publications
Dairy consumption and mortality after myocardial infarction: a prospective analysis in the Alpha Omega Cohort. Am J Clin Nutr. 2021;114:59-69 March 22, 2022 Dairy consumption and mortality after myocardial infarction: a prospective analysis in the Alpha Omega Cohort. Am J Clin Nutr. 2021;114:59-69 Cruijsen E, Jacobo Cejudo MG, Küpers LK, Busstra MC, Geleijnse JM Key Publications
Mechanistic insights from REDUCE-IT STRENGTHen the case against triglyceride lowering as a strategy for cardiovascular disease risk reduction. Am J Med. 2021;134:1085-1090 March 16, 2022 Mechanistic insights from REDUCE-IT STRENGTHen the case against triglyceride lowering as a strategy for cardiovascular disease risk reduction. Am J Med. 2021;134:1085-1090 Mason RP, Eckel RH Key Publications
Effect of exercise training on ambulatory blood pressure among patients with resistant hypertension: A randomized clinical trial. JAMA Cardiol. 2021;6:1317-1323 March 09, 2022 Effect of exercise training on ambulatory blood pressure among patients with resistant hypertension: A randomized clinical trial. JAMA Cardiol. 2021;6:1317-1323 Lopes S, Mesquita-Bastos J, Garcia C, Bertoquini S, Ribau V, Teixeira M, Ribeiro IP, Melo JB, Oliveira J, Figueiredo D, Guimarães GV, Pescatello LS, Polonia J, Alves AJ, Ribeiro F Key Publications
Use of lipid-lowering therapies over 2 years in GOULD, a registry of patients with atherosclerotic cardiovascular disease in the US. JAMA Cardiol. 2021:e211810 January 11, 2022 Use of lipid-lowering therapies over 2 years in GOULD, a registry of patients with atherosclerotic cardiovascular disease in the US. JAMA Cardiol. 2021:e211810 Cannon CP, de Lemos JA, Rosenson RS, Ballantyne CM, Liu Y, Gao Q, Palagashvilli T, Alam S, Mues KE, Bhatt DL, Kosiborod MN; GOULD Investigators Key Publications
Inhibiting interleukin-6 to reduce cardiovascular event rates: A next step for atherothrombosis treatment and prevention. J Am Coll Cardiol. 2021;77:1856-1858 October 07, 2021 Inhibiting interleukin-6 to reduce cardiovascular event rates: A next step for atherothrombosis treatment and prevention. J Am Coll Cardiol. 2021;77:1856-1858 Ridker PM Key Publications
Randomized trial of interleukin-6 receptor inhibition in patients with acute ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2021;77:1845-1855 October 06, 2021 Randomized trial of interleukin-6 receptor inhibition in patients with acute ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2021;77:1845-1855 Broch K, Anstensrud AK, Woxholt S, Sharma K, Tøllefsen IM, Bendz B, Aakhus S, Ueland T, Amundsen BH, Damås JK, Berg ES, Bjørkelund E, Bendz C, Hopp E, Kleveland O, Stensæth KH, Opdahl A, Kløw NE, Seljeflot I, Andersen GØ, Wiseth R, Aukrust P, Gullestad L Key Publications

  of 187 Next page

Go to page: of